Rodriguez Relays Insight Into the Integration of Immunotherapy in Lung Cancer

February 18, 2021
OncLive Staff

Partner | Cancer Centers | <b>Sylvester Comprehensive Cancer Center</b>

In our exclusive interview, Dr. Rodriguez discusses historic treatments in lung cancer that preceded the integration of immunotherapy, shares current treatment selection and sequencing strategies, and forecasts the future of immunotherapy in the field.

Welcome to OncLive On Air! I’m your host today, Jessica Hergert.

OncLive On Air is a podcast from OncLive®, which provides oncology professionals with the resources and information they need to provide the best patient care. In both digital and print formats, OncLive covers every angle of oncology practice, from new technology to treatment advances to important regulatory decisions.

In today’s episode, sponsored by Bristol Myers Squibb, we had the pleasure of speaking with Estelamari Rodriguez, MD, MPH, associate director of Community Outreach at Sylvester Comprehensive Cancer Center within the University of Miami Health System, to discuss the history of immuno-oncology in thoracic oncology.

In our exclusive interview, Rodriguez discussed historic treatments in lung cancer that preceded the integration of immunotherapy, shared current treatment selection and sequencing strategies, and forecasted the future of immunotherapy in the field.

x